Antiretroviral resistance in HIV: Difference between revisions
From IDWiki
(→) |
m (Aidan moved page Antiretroviral resistance to Antiretroviral resistance in HIV) |
||
(One intermediate revision by the same user not shown) | |||
Line 29: | Line 29: | ||
|- |
|- |
||
| rowspan="7" |69 insertion complex |
| rowspan="7" |69 insertion complex |
||
|M |
|M'''41L''' |
||
| rowspan="7" |multi-NRTI resistance |
| rowspan="7" |multi-NRTI resistance |
||
|- |
|- |
||
|A |
|A'''62V''' |
||
|- |
|- |
||
|* '''69''' '''insert''' |
|* '''69''' '''insert''' |
||
|- |
|- |
||
|K |
|K'''70R''' |
||
|- |
|- |
||
|L |
|L'''210W''' |
||
|- |
|- |
||
|T |
|T'''215YF''' |
||
|- |
|- |
||
|K |
|K'''219QE''' |
||
|- |
|- |
||
| rowspan="5" |151 complex |
| rowspan="5" |151 complex |
||
|A |
|A'''62V''' |
||
| rowspan="5" |multi-NRTI resistance |
| rowspan="5" |multi-NRTI resistance |
||
|- |
|- |
||
|V |
|V'''75I''' |
||
|- |
|- |
||
|F |
|F'''77L''' |
||
|- |
|- |
||
|F |
|F'''116Y''' |
||
|- |
|- |
||
|Q |
|Q'''151M''' |
||
|- |
|- |
||
| rowspan="6" |Thymidine analogue-associated mutations (TAMs) |
| rowspan="6" |Thymidine analogue-associated mutations (TAMs) |
||
|M |
|M'''41L''' |
||
| rowspan="6" |resistance to AZT and d4T; resistance to others is proportional to the number of TAMs, and with 4 or more mutations there is resistance to essentially all NRTIs |
| rowspan="6" |resistance to AZT and d4T; resistance to others is proportional to the number of TAMs, and with 4 or more mutations there is resistance to essentially all NRTIs |
||
|- |
|- |
||
|D |
|D'''67N''' |
||
|- |
|- |
||
|K |
|K'''70R''' |
||
|- |
|- |
||
|L |
|L'''210W''' |
||
|- |
|- |
||
|T |
|T'''215Y/F''' |
||
|- |
|- |
||
|K |
|K'''219Q/W''' |
||
|- |
|- |
||
| rowspan="4" |[[Abacavir]] |
| rowspan="4" |[[Abacavir]] |
||
|K |
|K'''65R/E/N''' |
||
|common |
|common |
||
|- |
|- |
||
|L |
|L'''74V''' |
||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''115F''' |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''184V''' |
||
|common; can still use TDF, AZT |
|common; can still use TDF, AZT |
||
|- |
|- |
||
| rowspan="2" |[[Emtricitabine]] |
| rowspan="2" |[[Emtricitabine]] |
||
|K |
|K'''65R/E/N''' |
||
|common |
|common |
||
|- |
|- |
||
|M |
|M'''184V/I''' |
||
|common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF |
|common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF |
||
|- |
|- |
||
| rowspan="2" |[[Lamivudine]] |
| rowspan="2" |[[Lamivudine]] |
||
|K |
|K'''65'''R/E/N |
||
|common |
|common |
||
|- |
|- |
||
|M |
|M'''184V/I''' |
||
|common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF |
|common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF |
||
|- |
|- |
||
| rowspan="2" |[[Tenofovir]] |
| rowspan="2" |[[Tenofovir]] |
||
|K |
|K'''65R/E/N''' |
||
|common |
|common |
||
|- |
|- |
||
|K |
|K'''70E''' |
||
| |
| |
||
|- |
|- |
||
| rowspan="6" |[[Zidovudine]] |
| rowspan="6" |[[Zidovudine]] |
||
|M |
|M'''41L''' |
||
| |
| |
||
|- |
|- |
||
|D |
|D'''67N''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''70R''' |
||
| |
| |
||
|- |
|- |
||
|L |
|L'''210W''' |
||
| |
| |
||
|- |
|- |
||
|T |
|T'''215Y/F''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''219Q/E''' |
||
| |
| |
||
|- |
|- |
||
Line 126: | Line 126: | ||
|- |
|- |
||
| rowspan="7" |[[Doravirine]] |
| rowspan="7" |[[Doravirine]] |
||
|V |
|V'''106A'''/I/'''M'''/T |
||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''188'''C/'''L'''/H |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''190'''E |
||
| |
| |
||
|- |
|- |
||
|P |
|P'''225'''H |
||
| |
| |
||
|- |
|- |
||
|F |
|F'''227'''C/L/R |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''230'''L |
||
| |
| |
||
|- |
|- |
||
|L |
|L'''234'''I |
||
| |
| |
||
|- |
|- |
||
| rowspan="10" |[[Efavirenz]] |
| rowspan="10" |[[Efavirenz]] |
||
|L |
|L'''100I''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''101P''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''103N'''/'''S''' |
||
| |
| |
||
|- |
|- |
||
|V |
|V'''106M''' |
||
| |
| |
||
|- |
|- |
||
|V |
|V'''108I''' |
||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''181C'''/'''I''' |
||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''188L''' |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''190S'''/'''A''' |
||
| |
| |
||
|- |
|- |
||
|P |
|P'''225H''' |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''230L''' |
||
| |
| |
||
|- |
|- |
||
| rowspan="9" |[[Nevirapine]] |
| rowspan="9" |[[Nevirapine]] |
||
|L |
|L'''100I''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''101P''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''103N'''/'''S''' |
||
| |
| |
||
|- |
|- |
||
|V |
|V'''106A'''/'''M''' |
||
| |
| |
||
|- |
|- |
||
|V |
|V'''108I''' |
||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''181C'''/'''I''' |
||
|common |
|common |
||
|- |
|- |
||
|Y |
|Y'''188C'''/'''L'''/'''H''' |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''190A''' |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''230L''' |
||
| |
| |
||
|- |
|- |
||
| rowspan="9" |[[Rilpivirine]] |
| rowspan="9" |[[Rilpivirine]] |
||
|L |
|L'''100I''' |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''101E'''/'''P''' |
||
|common |
|common |
||
|- |
|- |
||
|E |
|E'''138A'''/'''G'''/'''K'''/'''Q'''/'''R''' |
||
|common |
|common |
||
|- |
|- |
||
|V |
|V'''179L''' |
||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''181C'''/'''I'''/'''V''' |
||
|common |
|common |
||
|- |
|- |
||
|Y |
|Y'''188L''' |
||
| |
| |
||
|- |
|- |
||
|H |
|H'''221Y''' |
||
| |
| |
||
|- |
|- |
||
|F |
|F'''227C''' |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''230I'''/'''L''' |
||
| |
| |
||
|- |
|- |
||
Line 237: | Line 237: | ||
|- |
|- |
||
| rowspan="24" |[[Atazanavir]] |
| rowspan="24" |[[Atazanavir]] |
||
|L |
|L'''10'''I/F/V/C |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''16'''E |
||
| |
| |
||
|- |
|- |
||
|K |
|K'''20'''R/M/I/T/V |
||
| |
| |
||
|- |
|- |
||
|L |
|L'''24'''I |
||
| |
| |
||
|- |
|- |
||
|V |
|V'''32'''I |
||
| |
| |
||
|- |
|- |
||
|L |
|L'''33'''I/F/V |
||
| |
| |
||
|- |
|- |
||
|E |
|E'''34'''Q |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''36'''I/L/V |
||
| |
| |
||
|- |
|- |
||
|M |
|M'''46'''I/L |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''48'''V |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''50L''' |
||
|common |
|common |
||
|- |
|- |
||
|F |
|F'''53'''L/Y |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''54'''L/V/M/T/A |
||
| |
| |
||
|- |
|- |
||
|D |
|D'''60'''E |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''62'''V |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''64'''L/M/V |
||
| |
| |
||
|- |
|- |
||
|A |
|A'''71'''V/I/T/L |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''73'''C/S/T/A |
||
| |
| |
||
|- |
|- |
||
| |
|V82A/T/F/I |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''84V''' |
||
| |
| |
||
|- |
|- |
||
|I85V |
|||
|I 85 V |
|||
| |
| |
||
|- |
|- |
||
|N |
|N'''88S''' |
||
| |
| |
||
|- |
|- |
||
|L90M |
|||
|L 90 M |
|||
| |
| |
||
|- |
|- |
||
| |
|I93L/M |
||
| |
| |
||
|- |
|- |
||
| rowspan="10" |[[Darunavir]] |
| rowspan="10" |[[Darunavir]] |
||
|V11I |
|||
|V 11 I |
|||
| |
| |
||
|- |
|- |
||
|V32I |
|||
|V 32 I |
|||
| |
| |
||
|- |
|- |
||
|L33F |
|||
|L 33 F |
|||
| |
| |
||
|- |
|- |
||
|I |
|I'''47V''' |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''50V''' |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''54M'''/'''L''' |
||
| |
| |
||
|- |
|- |
||
|T74P |
|||
|T 74 P |
|||
| |
| |
||
|- |
|- |
||
|L |
|L'''76V''' |
||
| |
| |
||
|- |
|- |
||
|I |
|I'''84V''' |
||
| |
| |
||
|- |
|- |
||
|L89V |
|||
|L 89 V |
|||
| |
| |
||
|- |
|- |
||
Line 343: | Line 343: | ||
|- |
|- |
||
| rowspan="5" |[[Bictegravir]] |
| rowspan="5" |[[Bictegravir]] |
||
|G118R |
|||
|G 118 R |
|||
| |
| |
||
|- |
|- |
||
|E138K |
|||
|E 138 K |
|||
| |
| |
||
|- |
|- |
||
|G140S |
|||
|G 140 S |
|||
| |
| |
||
|- |
|- |
||
|Q |
|Q'''148H''' |
||
| |
| |
||
|- |
|- |
||
|R |
|R'''263K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan="8" |[[Cabotegravir]] |
| rowspan="8" |[[Cabotegravir]] |
||
|T66K |
|||
|T 66 K |
|||
| |
| |
||
|- |
|- |
||
|G |
|G'''118R''' |
||
| |
| |
||
|- |
|- |
||
| |
|E138A/K/T |
||
| |
| |
||
|- |
|- |
||
|G |
|G'''140'''A/C/'''R'''/S |
||
| |
| |
||
|- |
|- |
||
|Q |
|Q'''148H'''/'''K/R''' |
||
| |
| |
||
|- |
|- |
||
|S153F/Y |
|||
|S 153 F Y |
|||
| |
| |
||
|- |
|- |
||
|N155H |
|||
|N 155 H |
|||
| |
| |
||
|- |
|- |
||
|R |
|R'''263K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan="7" |[[Dolutegravir]] |
| rowspan="7" |[[Dolutegravir]] |
||
|G |
|G'''118R''' |
||
| |
| |
||
|- |
|- |
||
|F121Y |
|||
|F 121 Y |
|||
| |
| |
||
|- |
|- |
||
| |
|E138A/K/T |
||
| |
| |
||
|- |
|- |
||
|G140A/S |
|||
|G 140 A S |
|||
| |
| |
||
|- |
|- |
||
|Q |
|Q'''148H'''/'''K'''/'''R''' |
||
| |
| |
||
|- |
|- |
||
|N155H |
|||
|N 155 H |
|||
| |
| |
||
|- |
|- |
||
|R |
|R'''263K''' |
||
|common |
|common |
||
|- |
|- |
||
| rowspan="8" |[[Elvitegravir]] |
| rowspan="8" |[[Elvitegravir]] |
||
|T |
|T'''66I'''/A/K |
||
| |
| |
||
|- |
|- |
||
|E |
|E'''92Q'''/G |
||
| |
| |
||
|- |
|- |
||
|T97A |
|||
|T 97 A |
|||
| |
| |
||
|- |
|- |
||
|F |
|F'''121Y''' |
||
| |
| |
||
|- |
|- |
||
|S |
|S'''147G''' |
||
| |
| |
||
|- |
|- |
||
|Q |
|Q'''148H'''/'''K'''/'''R''' |
||
|common |
|common |
||
|- |
|- |
||
|N |
|N'''155H''' |
||
|common |
|common |
||
|- |
|- |
||
|R |
|R'''263K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan="10" |[[Raltegravir]] |
| rowspan="10" |[[Raltegravir]] |
||
|L74M |
|||
|L 74 M |
|||
| |
| |
||
|- |
|- |
||
|E92Q |
|||
|E 92 Q |
|||
| |
| |
||
|- |
|- |
||
|T97A |
|||
|T 97 A |
|||
| |
| |
||
|- |
|- |
||
|F |
|F'''121Y''' |
||
| |
| |
||
|- |
|- |
||
|E138A/K |
|||
|E 138 A K |
|||
| |
| |
||
|- |
|- |
||
|G140A/S |
|||
|G 140 A S |
|||
| |
| |
||
|- |
|- |
||
|Y |
|Y'''143R'''/'''H'''/'''C''' |
||
|common |
|common |
||
|- |
|- |
||
|Q |
|Q'''148H'''/'''K'''/'''R''' |
||
|common |
|common |
||
|- |
|- |
||
|N |
|N'''155H''' |
||
|common |
|common |
||
|- |
|- |
||
|R |
|R'''263K''' |
||
| |
| |
||
|} |
|} |
Latest revision as of 12:59, 22 October 2020
- Genotyping sequences reverse transcriptase, integrase, and protease
- Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K 103 N)
- Bulk sequencing can only detect mutations that represent >20% of HIV
Common Mutations
- NRTIs
- M184V/I confers resistance to lamivudine, emtricitabine, and abacavir, but increases susceptibility to tenofovir, so combinations that include tenofovir are still safe to use
- K65R confers resistance to lamivudine, emtricitabine, and abacavir
- TAMS (M41L, D76N, K70R, L210W, T215Y, K219Q) confer resistance to basically all NRTIs as they increase in number
- Q151M, 69SSS confers resistance to NRTIs
- NNRTIs
- K103N confers resistance to efavirenz and nevirapine
- Y181C confers resistance to nevirapine and other NNRTIs
- E138K and K101E confer resistance to rilpivirine and other NNRTIs
- I50L confers resistance to atazanavir
- INSTIs
- N155H and Q148H/R?K confer resistance to raltegravir and elvitegravir
- Y143C confers resistance to raltegravir
- R263K confers resistance to dolutegravir
All Mutations
Drug | Mutation | Notes |
---|---|---|
NRTIs | ||
69 insertion complex | M41L | multi-NRTI resistance |
A62V | ||
* 69 insert | ||
K70R | ||
L210W | ||
T215YF | ||
K219QE | ||
151 complex | A62V | multi-NRTI resistance |
V75I | ||
F77L | ||
F116Y | ||
Q151M | ||
Thymidine analogue-associated mutations (TAMs) | M41L | resistance to AZT and d4T; resistance to others is proportional to the number of TAMs, and with 4 or more mutations there is resistance to essentially all NRTIs |
D67N | ||
K70R | ||
L210W | ||
T215Y/F | ||
K219Q/W | ||
Abacavir | K65R/E/N | common |
L74V | ||
Y115F | ||
M184V | common; can still use TDF, AZT | |
Emtricitabine | K65R/E/N | common |
M184V/I | common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF | |
Lamivudine | K65R/E/N | common |
M184V/I | common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF | |
Tenofovir | K65R/E/N | common |
K70E | ||
Zidovudine | M41L | |
D67N | ||
K70R | ||
L210W | ||
T215Y/F | ||
K219Q/E | ||
NNRTIs | ||
Doravirine | V106A/I/M/T | |
Y188C/L/H | ||
G190E | ||
P225H | ||
F227C/L/R | ||
M230L | ||
L234I | ||
Efavirenz | L100I | |
K101P | ||
K103N/S | ||
V106M | ||
V108I | ||
Y181C/I | ||
Y188L | ||
G190S/A | ||
P225H | ||
M230L | ||
Nevirapine | L100I | |
K101P | ||
K103N/S | ||
V106A/M | ||
V108I | ||
Y181C/I | common | |
Y188C/L/H | ||
G190A | ||
M230L | ||
Rilpivirine | L100I | |
K101E/P | common | |
E138A/G/K/Q/R | common | |
V179L | ||
Y181C/I/V | common | |
Y188L | ||
H221Y | ||
F227C | ||
M230I/L | ||
Protease inhibitors | ||
Atazanavir | L10I/F/V/C | |
G16E | ||
K20R/M/I/T/V | ||
L24I | ||
V32I | ||
L33I/F/V | ||
E34Q | ||
M36I/L/V | ||
M46I/L | ||
G48V | ||
I50L | common | |
F53L/Y | ||
I54L/V/M/T/A | ||
D60E | ||
I62V | ||
I64L/M/V | ||
A71V/I/T/L | ||
G73C/S/T/A | ||
V82A/T/F/I | ||
I84V | ||
I85V | ||
N88S | ||
L90M | ||
I93L/M | ||
Darunavir | V11I | |
V32I | ||
L33F | ||
I47V | ||
I50V | ||
I54M/L | ||
T74P | ||
L76V | ||
I84V | ||
L89V | ||
INSTIs | ||
Bictegravir | G118R | |
E138K | ||
G140S | ||
Q148H | ||
R263K | ||
Cabotegravir | T66K | |
G118R | ||
E138A/K/T | ||
G140A/C/R/S | ||
Q148H/K/R | ||
S153F/Y | ||
N155H | ||
R263K | ||
Dolutegravir | G118R | |
F121Y | ||
E138A/K/T | ||
G140A/S | ||
Q148H/K/R | ||
N155H | ||
R263K | common | |
Elvitegravir | T66I/A/K | |
E92Q/G | ||
T97A | ||
F121Y | ||
S147G | ||
Q148H/K/R | common | |
N155H | common | |
R263K | ||
Raltegravir | L74M | |
E92Q | ||
T97A | ||
F121Y | ||
E138A/K | ||
G140A/S | ||
Y143R/H/C | common | |
Q148H/K/R | common | |
N155H | common | |
R263K |